title: Plasma caffeic acid is associated with statistical clustering of the anticolitic efficacy of caffeic acid in dextran sulfate sodium-treated mice.
abstract: We hypothesized that interindividual variability in the bioavailability of caffeic acid (CA) would influence its anticolitic efficacy and that mice may be appropriate for modeling human gut microbial metabolism of CA, which is thought to influence CA bioavailability. Anaerobic human fecal and mouse cecal sample mixtures were incubated with CA derivatives from Echinacea purpurea and compound disappearance rates were measured, which were similar in both sample types. CA metabolism, including formation of its main metabolite, m-hydroxyphenylpropionate, in the mouse cecum may usefully model human gut metabolism of this compound. Ten-week-old CD-1/IGS female mice were fed 120 mg CA/kg (n = 36) or control diet for 7 d (n = 12); one-half of each group then drank 1.25% dextran sulfate sodium (DSS) in water for 5 d. DSS-treated mice fed CA showed lessened colitic damage than did mice given DSS alone, with longer colons, greater body weight, and colonic Cyp4b1 expression. Cluster analysis of the cecal histopathological score showed that mice with severe cecal damage (mean cecal score = 8.5; n = 11) also had greater myeloperoxidase (MPO) activity and lower plasma CA compared with mice showing mild cecal damage (mean cecal score = 4.5; n = 4) (P < 0.05). Cecal score was positively correlated with colonic MPO activity (r = 0.72; P < 0.05) and negatively correlated with plasma CA (r = -0.57; P < 0.05). These studies indicated that the anticolitic efficacy of CA was related to variability in CA bioavailability, which may be influenced by gut microbial metabolism of this compound.
authors.affiliation: Department of Nutrition, University of California, Davis, CA, USA.
authors.forename: Zhong
authors.initials: Z
authors.lastname: Ye
authors.forename: Chung-Oui
authors.initials: CO
authors.lastname: Hong
authors.forename: Kwangwon
authors.initials: K
authors.lastname: Lee
authors.forename: Jesse
authors.initials: J
authors.lastname: Hostetter
authors.forename: Michael
authors.initials: M
authors.lastname: Wannemuehler
authors.forename: Suzanne
authors.initials: S
authors.lastname: Hendrich
mesh_terms: D000818:Animals; D001682:Biological Availability; D002109:Caffeic Acids / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D016000:Cluster Analysis; D003092:Colitis / Q000188:drug therapy*; D016264:Dextran Sulfate / Q000008:administration & dosage*; D005260:Female; D051379:Mice; D016133:Polymerase Chain Reaction
chemical_list: D002109:Caffeic Acids; D016264:Dextran Sulfate; C040048:caffeic acid